Clinical Trial Update: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BCX9930 for Paroxysmal Nocturnal Hemoglobinuria in participants not receiving other complement inhibitors was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: TERMINATED | Results posted: 2025-01-03